FDA grants fast track designation to BioAlliance's cancer drug Validive
from Pharmaceutical Business Review
BioAlliance Pharma, an innovative company dedicated to the development of orphan oncology, announced that Validive received a fast track designation from the U.S. Food and Drug Administration for the prevention and treatment of oral mucositis induced by radiotherapy and/or chemotherapy in cancer patients.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063